NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Eflornithine in Treating Patients With Bladder Cancer

Phase 3

Completed

Conditions: Bladder Cancer

First Posted Date: 2004-02-20

Last Posted Date: 2013-12-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 450

Registration Number: NCT00003814

Locations: 🇺🇸
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Simmons Cancer Center - Dallas, Dallas, Texas, United States
🇺🇸
Piedmont Urology PC, Atlanta, Georgia, United States

and more 58 locations

Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: recombinant vaccinia-B7.1 vaccine

First Posted Date: 2004-02-20

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00004148

Locations: 🇺🇸
Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States

Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: bortezomib
Drug: fluorouracil
Drug: leucovorin calcium
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2004-02-16

Last Posted Date: 2013-12-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00007878

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States

506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Drug: nelarabine

First Posted Date: 2004-02-16

Last Posted Date: 2013-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00003545

Locations: 🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸
CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States

and more 88 locations

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Lymphocytic
Leukemia
Chronic

Interventions: Drug: LMB-2

First Posted Date: 2004-02-13

Last Posted Date: 2018-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT00077922

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer

Phase 2

Completed

Conditions: Male Breast Cancer
Stage IV Breast Cancer
HER2-positive Breast Cancer
Recurrent Breast Cancer

Interventions: Biological: trastuzumab
Drug: ixabepilone
Drug: carboplatin
Other: laboratory biomarker analysis

First Posted Date: 2004-02-12

Last Posted Date: 2014-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 61

Registration Number: NCT00077376

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction

Phase 2

Completed

Conditions: Adenocarcinoma of the Esophagus
Recurrent Esophageal Cancer
Stage IV Esophageal Cancer

Interventions: Drug: triapine
Drug: cisplatin

First Posted Date: 2004-02-12

Last Posted Date: 2013-10-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 39

Registration Number: NCT00077545

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck

Phase 2

Completed

Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Recurrent Salivary Gland Cancer
Salivary Gland Adenoid Cystic Carcinoma
Stage III Adenoid Cystic Carcinoma of the Oral Cavity
Stage III Salivary Gland Cancer
Stage IV Adenoid Cystic Carcinoma of the Oral Cavity
Stage IV Salivary Gland Cancer

Interventions: Drug: bortezomib
Drug: doxorubicin hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2004-02-12

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00077428

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy

Phase 1

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Drug: cisplatin
Drug: irinotecan hydrochloride
Drug: amifostine trihydrate
Other: pharmacological study

First Posted Date: 2004-02-12

Last Posted Date: 2013-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00004919

Locations: 🇺🇸
COG Phase I Consortium, Arcadia, California, United States

Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia

Phase 1

Completed

Conditions: Blastic Phase Chronic Myelogenous Leukemia
Childhood Acute Promyelocytic Leukemia (M3)
Recurrent Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood Acute Myeloid Leukemia

Interventions: Drug: bortezomib
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2004-02-12

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00077467

Locations: 🇺🇸
COG Phase I Consortium, Arcadia, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy